Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07307469 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Compassionate Administration of ZVS101e for Extended Treatment

StatusEnrolling by Invitation
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modifiedv2 Show 4 more changesShow less
    • Start date: Mar 2026 to Jul 2026
    • Eligibility criteria shortened, about 3 words
    • Study description expanded, about 1 word
    • Study title shortened, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To provide treatment options for the control group of subjects who completed the 52-week follow-up of the Phase III clinical trial (Protocol number: ZYA-2024-001) of ZVS101e in subjects with Bietti crystalline corneoretinal dystrophy (BCD).
Trial Details
NCT Number NCT07307469
Lead Sponsor Chigenovo Co., Ltd
Conditions
(from sponsor)		 Bietti Crystalline Corneoretinal Dystrophy
Related terms Bietti Crystalline Dystrophy
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov